[Pathogenesis of non-alcoholic fatty liver and potential therapeutic targets].
Crespo
J
J
Servicio de Aparato Digestivo, Hospital Universitario Marqués de Valdecilla, Santander, España. javiercrespo@teleline.es
Cayón
A
A
Pons-Romero
F
F
D000975:Antioxidants / Q000627:therapeutic use; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000188:drug therapy; D018450:Disease Progression; D005230:Fatty Acids, Nonesterified / Q000378:metabolism; D005234:Fatty Liver / Q000209:etiology* / Q000628:therapy; D022781:Hepatocytes / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007333:Insulin Resistance; D015227:Lipid Peroxidation; D008099:Liver / Q000378:metabolism; D008103:Liver Cirrhosis / Q000209:etiology; D008862:Microsomes, Liver / Q000378:metabolism; D008930:Mitochondria, Liver / Q000378:metabolism; D008954:Models, Biological; D009765:Obesity / Q000150:complications / Q000628:therapy; D010084:Oxidation-Reduction; D014280:Triglycerides / Q000378:metabolism
D000975:Antioxidants; D005230:Fatty Acids, Nonesterified; D007004:Hypoglycemic Agents; D014280:Triglycerides